Brain Tumor Program
The Pediatric Brain Tumor Program offers advanced treatments for brain and spinal cord tumors in a supportive environment. Our goal is to cure whenever possible while providing every patient with the best possible care and quality of life. We treat kids from all over the Bay Area and beyond.
Because these patients often need many types of treatment, our program brings together a highly experienced team of experts to provide coordinated care. Pediatric neuro-oncologists (specialists in brain and spinal cancers) collaborate closely with doctors from pediatric neurosurgery, pediatric neurology, pediatric physical medicine and rehabilitation, and pediatric radiation oncology on every case to deliver an accurate diagnosis and design an effective treatment plan.
The team also includes psychologists, neuropsychologists, social workers, child life specialists and a school liaison. These experts help families navigate the challenges of treatment while looking after their child's emotional and psychological health. We work with local and national organizations to ensure patients and their families have the resources they need, including support groups.
Highlights of the Pediatric Brain Tumor Program
We have expertise in leading-edge diagnostic methods, such as:
- Stereotactic biopsy. Compared with open surgery, this is a less invasive method for obtaining a sample of tumor tissue for microscopic analysis. The surgeon makes a small hole in the skull and, guided by imaging, uses a needle to remove some tumor cells.
- Gene sequencing. For all our patients, we use a state-of-the-art test, the UCSF500 Cancer Gene Panel, to identify mutations in the tumor's DNA. The results can allow doctors to make more accurate diagnoses and determine the best treatment course for an individual patient.
We provide innovative brain tumor treatments, including:
- Metaiodobenzylguanidine (MIBG). Only a few hospitals in California offer this drug, which targets treatment-resistant neuroblastoma.
- Convection-enhanced delivery. Researchers at UCSF helped pioneer this procedure, which uses a thin tube to administer chemotherapy drugs directly to a brain tumor, making the treatment more effective while reducing its side effects on healthy brain tissue and the rest of the body.
- MEK inhibitors. These drugs, which block the activity of certain proteins, can effectively treat neurofibromatosis type 1.
We take advantage of technologies that can optimize what a treatment achieves while minimizing its harmful side effects. Examples include:
- MRI scanning during procedures. This practice helps surgeons safely remove as much of the tumor as possible.
- Gamma Knife and CyberKnife radiosurgery. We are one of only a few centers in California to offer these advanced techniques, either of which may be an option for tumors previously considered untreatable. They allow precise delivery of high-dose radiation therapy with minimal damage to healthy tissues.
What's more, our program is committed to improving brain tumor care through research. We belong to several national alliances for brain tumor investigation, and UCSF Benioff Children's Hospitals play a leading role in the Pacific Pediatric Neuro-Oncology Consortium, which is dedicated to developing innovative treatments for these cancers. This active involvement means our patients have exceptional access to promising experimental therapies and are among the first to benefit from new scientific findings.
Your child may have the opportunity to participate in a clinical trial for a promising brain tumor treatment. Learn more about the process and potential benefits of participating in a clinical trial.
Our locations (2)
Explore what we do
Navigating brain tumor treatment with virtual reality
Our team used cutting-edge VR technology to help a patient with neurofibromatosis type 1 and her family prepare for brain surgery.
Our team
-
Sabine Mueller
MD, PhD, MAS
Pediatric neurologist and neuro-oncologist -
Kurtis Auguste
MD
Pediatric neurosurgeon -
Anuradha Banerjee
MD, MPH
Pediatric neuro-oncologist -
Mitchel Berger
MD
Neurosurgeon -
Steve Braunstein
MD, PhD
Radiation oncologist -
Nalin Gupta
MD, PhD
Pediatric neurosurgeon -
Caroline Hastings
MD
Hematologist-oncologist and neuro-oncologist -
Winson S. Ho
MD
Pediatric neurosurgeon -
Marie Jaeger-Krause
MD
Pediatric hematologist-oncologist and neuro-oncologist -
Maya Lodish
MD
Pediatric endocrinologist -
Brian S. Na
MD
Neuro-oncologist -
Jean L. Nakamura
MD
Radiation oncologist -
Bo Qiu
MD, PhD
Pediatric oncologist -
David R. Raleigh
MD, PhD
Radiation oncologist -
Alyssa Reddy
MD
Pediatric neurologist and neuro-oncologist -
Peter P. Sun
MD
Pediatric neurosurgeon -
Dina Hankin
PhD
Psychologist -
Shannon Lundy
PhD
Pediatric neuropsychologist -
Wendy Santos-Modesitt
PhD
Pediatric neuropsychologist -
Caroline Farless
PNP, RN
Pediatric nurse practitioner -
Carly Hoffman
PNP, MSN
Pediatric nurse practitioner -
Stephanie Petruzzi
LCSW, MSW
Pediatric social worker -
Shannon H. Raber
PNP, MSN
Pediatric nurse practitioner -
Sarah Schleimer
PNP, MSN
Pediatric nurse practitioner
Awards & recognition
-
Ranked among the nation's best in 11 specialties
-
Best in Northern California for cancer care
-
One of the nation's best for neurology & neurosurgery
-
in NIH funding among U.S. neurology programs
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
Clinical trials
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Will be measured by the number of progressions or deaths within 2 years of enrollment for the cohort treated with whole ventricular + spinal canal irradiation (WVSCI). The final analysis will include an exact binomial confidence i...
Recruiting
More about this studyGenetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients Wit...
MTD is defined as the dose at which fewer than one-third of participants experience a dose limiting toxicity (DLT) for all participants who received at least one study intervention.
Recruiting
More about this studyBGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...
Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.
Recruiting
More about this studyCombination Therapy for the Treatment of Diffuse Midline Gliomas
Percentage of participants alive and free from progression at 6 months after the initiation of the combination of the backbone (i.e., ONC201) with a novel agent given in the maintenance phase of therapy. The primary analysis for P...
Recruiting
More about this studyImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Gli...
Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments when compared to archived recurrent pediatric HGG group. The number of participants with high cell cycle gene ...
Recruiting
More about this studyNivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Progression-free survival is defined as the time of documented response until disease progression as defined by Response assessment in neuro-oncology criteria (RANO) criteria. PFS will be reported by overall group at 12 months.
Recruiting
More about this studyIntra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
Adverse events and clinically significant laboratory abnormalities (meeting grade 3, 4, or 5 criteria according to NCI CTCAE) will be summarized by maximum intensity and relationship to study drug(s). Grade 1 and 2 adverse events ...
Recruiting
More about this studyTrametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gl...
We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...
Recruiting
More about this studyA Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary C...
We will estimate the difference in mean Cogstate composite Z score slopes (reflecting change in Cogstate composite Z scores from baseline to 12 months post baseline taking into account measurements at those time points as well as ...
Recruiting
More about this studyA Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary C...
We will estimate the difference in mean Cogstate composite Z score slopes (reflecting change in Cogstate composite Z scores from baseline to 12 months post baseline taking into account measurements at those time points as well as ...
Recruiting
More about this studySupport services
Our research initiatives
Smell the roses